Abstrakt

Przypisy

• 1. Banchereau J., Steinman R.M.: Dendritic cells and the control ofimmunity. Nature, 1998; 392: 245-252
  Google Scholar
• 2. Bianchi A., Mariani S., Beggiato E., Borrione E., Peola S., BoccadoroM., Pileri A., Massaia M.: Distribution of T-cell signalling moleculesin human myeloma. Br. J. Haematol., 1997; 97: 815-820
  Google Scholar
• 3. Bianchi A., Montacchini L., Barral P., Borrione P., Attisano C.,Orsini E., Boccadoro M., Pileri A., Massaia M.: CD3-induced T-cellactivation in the bone marrow of myeloma patients: major role ofCD4+ cells. Br. J. Haematol., 1995; 90: 625-632
  Google Scholar
• 4. Bielawska-Pohl A., Pajtasz-Piasecka E., Duś D.: Natural killer cellscomplot with dendritic cells. Postępy Hig. Med. Dośw., 2013; 67:192-200
  Google Scholar
• 5. Bodey B., Siegel S.E., Kaiser H.E.: Antigen presentation by dendriticcells and their significance in antineoplastic immunotherapy.In Vivo, 2004; 18: 81-100
  Google Scholar
• 6. Bommert K., Bargou R.C., Stühmer T.: Signalling and survivalpathways in multiple myeloma. Eur. J. Cancer, 2006; 42: 1574-1580
  Google Scholar
• 7. Brown R., Murray A., Pope B., Sze D.M., Gibson J., Ho P.J., HartD., Joshua D.: Either interleukin-12 or interferon-g can correct thedendritic cell defect induced by transforming growth factor β1 inpatients with myeloma. Br. J. Haematol., 2004; 125: 743-748
  Google Scholar
• 8. Brown R.D., Pope B., Murray A., Esdale W., Sze D.M., Gibson J., HoP.J., Hart D., Joshua D.: Dendritic cells from patients with myelomaare numerically normal but functionally defective as they fail to upregulateCD80 (B7-1) expression after huCD40LT stimulation becauseof inhibition by transforming growth factor-β1 and interleukin-10.Blood, 2001; 98: 2992-2998
  Google Scholar
• 9. Caers J., Van Valckenborgh E., Menu E., Van Camp B., VanderkerkenK.: Unraveling the biology of multiple myeloma disease: cancerReferencesstem cells, acquired intracellular changes and interactions with thesurrounding micro-environment. Bull. Cancer, 2008; 95: 301-313
  Google Scholar
• 10. Chapoval A.I., Tamada K., Chen L.: In vitro growth inhibition ofa broad spectrum of tumor cell lines by activated human dendriticcells. Blood, 2000; 95: 2346-2351
  Google Scholar
• 11. Chaux P., Favre N., Martin M., Martin F.: Tumor-infiltratingdendritic cells are defective in their antigen-presenting functionand inducible B7 expression in rats. Int. J. Cancer, 1997; 72: 619-624
  Google Scholar
• 12. Chomarat P., Banchereau J., Davoust J., Palucka A.K.: IL-6 switchesthe differentiation of monocytes from dendritic cells to macrophages.Nat. Immunol., 2000; 1: 510-514
  Google Scholar
• 13. Dhodapkar K.M., Barbuto S., Matthews P., Kukreja A., MazumderA., Vesole D., Jagannath S., Dhodapkar M.V.: Dendritic cells mediatethe induction of polyfunctional human IL17-producing cells (Th17-1cells) enriched in the bone marrow of patients with myeloma. Blood,2008; 112: 2878-2885
  Google Scholar
• 14. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fuji S.,Dhodapkar K.M., Krasovsky J.: A reversible defect in natural killerT cell function characterizes the progression of premalignant tomalignant multiple myeloma. J. Exp. Med., 2003; 197: 1667-1676
  Google Scholar
• 15. Fauriat C., Mallet F., Olive D., Costello R.T.: Impaired activatingreceptor expression pattern in natural killer cells from patients withmultiple myeloma. Leukemia, 2006; 20: 732-733
  Google Scholar
• 16. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., NadafS., Carbone D.P.: Vascular endothelial growth factor inhibits thedevelopment of dendritic cells and dramatically affects the differentiationof multiple hematopoietic lineages in vivo. Blood, 1998;92: 4150-4166
  Google Scholar
• 17. Hajek R., Butch A.W.: Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med.Oncol., 2000; 17: 2-15
  Google Scholar
• 18. Harrison S.J., Cook G.: Immunotherapy in multiple myeloma -possibility or probability? Br. J. Haematol., 2005; 130: 344-362
  Google Scholar
• 19. Hart D.N.: Dendritic cells: unique leukocyte populations whichcontrol the primary immune response. Blood, 1997; 90: 3245-3287
  Google Scholar
• 20. Jacobson D.R., Zolla-Pazner S.: Immunosupression and infectionin multiple myeloma. Semin. Oncol., 1986; 13: 282-290
  Google Scholar
• 21. Jurczyszyn A., Gdula-Argasińska J., Kosmaczewska A., SkotnickiA.B.: The role of the bone marrow microenvironment in the pathogenesisof multiple myeloma. Postępy Hig. Med. Dośw., 2015;69: 521-533
  Google Scholar
• 22. Jurczyszyn A., Kosmaczewska A., Skotnicki A.B.: Daratumumab -breakthrough drug in multiple myeloma therapy. Postępy Hig. Med.Dośw., 2014; 68: 1352-1360
  Google Scholar
• 23. Jurisic V., Srdic T., Konjevic G., Markovic O., Colovic M.: Clinicalstage-depending decrease of NK cell activity in multiple myelomapatients. Med. Oncol., 2007; 24: 312-317
  Google Scholar
• 24. Kay N.E., Leong T., Bone N., Kyle R.A., Greipp P.R., Van Ness B.,Oken M.M.: T-helper phenotypes in the blood of myeloma patientson ECOG phase III trials E9486/E3A93. Br. J. Haematol., 1998; 100:459-463
  Google Scholar
• 25. Kay N.E., Leong T.L., Bone N., Vesole D.H., Greipp P.R., Van NessB., Oken M.M., Kyle R.A.: Blood levels of immune cells predict survivalin myeloma patients: results of an Eastern Cooperative OncologyGroup phase 3 trial for newly diagnosed multiple myeloma patients.Blood, 2001; 98: 23-28
  Google Scholar
• 26. Kay N.E., Leong T., Kyle R.A., Greipp P., Billadeau D., Van Ness B.,Bone N., Oken M.M.: Circulating blood B cells in multiple myeloma:analysis and relationship to circulating clonal cells and clinical parametersin a cohort of patients entered on the Eastern CooperativeOncology Group phase III E9486 clinical trial. Blood, 1997; 90: 340-345
  Google Scholar
• 27. Kicielińska J., Pajtasz-Piasecka E.: The role of IL-10 in the modulationof the immune response in normal conditions and the tumorenvironment. Postępy Hig. Med. Dośw., 2014; 68: 879-892
  Google Scholar
• 28. King M.A., Radicchi-Mastroianni M.A.: Natural killer cells andCD56+ T cells in the blood of multiple myeloma patients: analysis by4-colour flow cytometry. 1996; 26: 121-124
  Google Scholar
• 29. Kuriyama Y., Kawanishi Y., Iwase O., Nakano M., Toyama K.: Immunoregulatorycells in patients with monoclonal gammopathies.Rinsho Ketsueki, 1994; 35: 642-648
  Google Scholar
• 30. Mozaffari F., Hansson L., Kiaii S., Ju X., Rossmann E.D., RabbaniH., Mellstedt H., Osterborg A.: Signalling molecules and cytokineproduction in T cells of multiple myeloma-increased abnormalitieswith advancing stage. Br. J. Haematol., 2004; 124: 315-324
  Google Scholar
• 31. Ogmundsdóttir H.M.: Natural killer cell activity in patients withmultiple myeloma. Cancer Detect. Prev., 1988; 12: 133-143
  Google Scholar
• 32. Palucka A.K., Ueno H., Fay J., Banchereau J.: Dendritic cells: acritical player in cancer therapy? J. Immunother., 2008; 31: 793-805
  Google Scholar
• 33. Pasiarski M., Grywalska E., Kosmaczewska A., Góźdź S., RolińskiJ.: The frequency of myeloid and lymphoid dendritic cells in multiplemyeloma patients is inversely correlated with disease progression.Postępy Hig. Med. Dośw., 2013; 67: 926-932
  Google Scholar
• 34. Pérez-Andres M., Almeida J., Martin-Ayuso M., Moro M.J., Martin-NuñezG., Galende J., Hernandez J., Mateo G., San Miguel J.F., OrfaoA.; Spanish Network on Multiple Myeloma; Spanish Network ofCancer Research Centers: Characterization of bone marrow T cellsin monoclonal gammopathy of undetermined significance, multiplemyeloma, and plasma cell leukemia demonstrates increasedinfiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβrepertoire. Cancer, 2006; 106: 1296-1305
  Google Scholar
• 35. Pratt G., Goodyear O., Moss P.: Immunodeficiency and immunotherapyin multiple myeloma. Br. J. Haematol., 2007; 138: 563-579
  Google Scholar
• 36. Raitakari M., Brown R.D., Gibson J., Joshua D.E.: T cells in myeloma.Hematol. Oncol., 2003; 21: 33-42
  Google Scholar
• 37. Rhee F.: Idiotype vaccination strategies in myeloma: how toovercome a dysfunctional immune system. Clin. Cancer Res., 2007;13: 1353-1355
  Google Scholar
• 38. Schütt P., Brandhorst D., Stellberg W., Poser M., Ebeling P., MüllerS., Buttkereit U., Opalka B., Lindemann M., Grosse-Wilde H., SeeberS., Moritz T., Nowrousian M.R.: Immune parameters in multiple myelomapatients: influence of treatment and correlation with opportunisticinfections. Leuk. Lymphoma, 2006; 47: 1570-1582
  Google Scholar
• 39. Spanoudakis E., Hu M., Naresh K., Terpos E., Melo V., Reid A.,Kotsianidis I., Abdalla S., Rahemtulla A., Karadimitris A.: Regulationof multiple myeloma survival and progression by CD1d. Blood,2009; 113: 2498-507
  Google Scholar
• 40. Sze D.M., Giesajtis G., Brown R.D., Raitakari M., Gibson J., HoJ., Baxter A.G., Fazekas de St Groth B., Basten A., Joshua D.E.: Clonalcytotoxic T cells are expanded in myeloma and reside in theCD8+CD57+CD28- compartment. Blood, 2001; 98: 2817-2827
  Google Scholar
• 41. Szmyrka-Kaczmarek M., Kosmaczewska A., Ciszak L., SzteblichA., Wiland P.: Peripheral blood Th17/Treg imbalance in patientswith low-active systemic lupus erythematosus. Postępy Hig. Med.Dośw., 2014; 68: 893-898
  Google Scholar
• 42. Tabarkiewicz J., Roliński J.: Rola komórek dendrytycznych wpatogenezie chorób człowieka i ich praktyczne wykorzystanie wimmunoterapii. Acta Haematol. Polonica, 2006; 37 (Suppl. 1): 195-202
  Google Scholar
• 43. Tessmer M.S., Fatima A., Paget C., Trottein F., Brossay L.: NKTcell immune responses to viral infection. Expert Opin. Ther. Targets,2009; 13: 153-162
  Google Scholar
• 44. Tian F., Dou C., Qi S., Chen B., Zhao L., Wang X.: Dendritic cell-gliomafusion activates T lymphocytes by elevating cytotoxic efficiencyas an antitumor vaccine. Centr. Eur. J. Immunol., 2014; 39: 265-270
  Google Scholar
• 45. Xie J., Wang Y., Freeman M.E. 3rd, Barlogie B., Yi Q.: β2-Microglobulin as a negative regulator of the immune system: highconcentrations of the protein inhibit in vitro generation of functionaldendritic cells. Blood, 2003; 101: 4005-4012
  Google Scholar
• 46. Yang D.H., Park J.S., Jin C.J., Kang H.K., Nam J.H., Rhee J.H., KimY.K., Chung S.Y., Choi S.J., Kim H.J., Chung I.J., Lee J.J.: The dysfunctionand abnormal signaling pathway of dendritic cells loaded bytumor antigen can be overcome by neutralizing VEGF in multiplemyeloma. Leuk. Res., 2009; 33: 665-670
  Google Scholar
• 47. Zheng C., Ostad M., Andersson M., Celsing F., Holm G., SundbladA.: Natural cytotoxicity to autologous antigen-pulsed dendritic cellsin multiple myeloma. Br. J. Haematol., 2002; 118: 778-785
  Google Scholar

Pełna treść artykułu